Oncology Drug Reference Sheet: Retifanlimab-Dlwr

In a clinical trial of 65 patients with metastatic or recurrent Merkel cell carcinoma who had not previously received systemic therapy for advanced disease, treatment with retifanlimab-dlwr (Zynyz^™) achieved a 52% overall response rate and 18% complete response rate, leading the U.S. Food and Drug Administration to grant it accelerated approval in March 2023.